Status:
COMPLETED
Quality of Life After Transanal Total Mesorectal Excision Compared to Traditional Total Mesorectal Excision
Lead Sponsor:
Cantonal Hospital of St. Gallen
Conditions:
Rectal Cancer
Quality of Life
Eligibility:
All Genders
18+ years
Brief Summary
The improvement in prognosis of rectal cancer through modern therapy modalities rises questions regarding quality of life (QoL) and functional outcomes. Evidence for long-term QoL and functional outco...
Detailed Description
Quality of life and functional outcomes of patients undergoing taTME or abTME for stage I-III rectal cancer will be analysed. A retrospective propensity score-adjusted analysis of prospectively conduc...
Eligibility Criteria
Inclusion
- elective total mesorectal excision followed by reconstruction with anastomosis for primary rectal cancer
Exclusion
- diagnoses other than rectal cancer
- recurrent rectal cancer
- partial mesorectal excision
- discontinuity resection (no anastomosis)
- incomplete TNM staging information
- metastatic cancer
- 30-day mortality
- lack of quality of life data
- patient decline
- age under 18 years
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2025
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT06505863
Start Date
August 1 2024
End Date
July 1 2025
Last Update
July 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cantonal Hospital of St.Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland, 9000